Next-Generation Psychedelics

Colorado and Leiden-based biotech company Mydecine Innovations Group (OTC: MYCOF) has shared its financial results and business highlights for the period ended December 31, 2022. In ciphers: Total assets of $4.6 (CA$6.2) million as of Dec. 2022, of which cash constituted $8,216; compared to $3.8...

Next-gen therapeutics developer Psilera Inc. has achieved a preclinical milestone by having all its first cohort of drug candidates, designed and synthesized in-house, show no hallucinogenic effects in animals. The group includes six patent-pending compounds with novel structural features...

Psyence Partners with iNGENū for Palliative Care Clinical Trial Life sciences biotech company Psyence Group Inc (OTCQB: PSYGF)’s wholly-owned Australian subsidiary Psyence Australia Pty Ltd. partnered with Contract Research Organization (CRO) iNGENū Pty Ltd to conduct a Phase 2b clinical...

Drug development biotech company Enveric Biosciences (NASDAQ: ENVB) has created Australia-based subsidiary Enveric Therapeutics Pty. Ltd. to support the progress of its next-generation psychedelics program for anxiety disorders, EVM201, towards the clinical stage. The series includes lead candidate...

Biopharma company Enveric Biosciences (NASDAQ: ENVB) has shared new findings involving the first-ever isolation of a specific enzyme from the cane toad, plus the successful development of a bioproduction platform for the isolation and pharmacological screening of novel molecules belonging to the...

Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey. Reunion alleges that Mindset purposefully copied its psychedelic compound RE104...

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial Short-acting psychedelics biotech company Small Pharma Inc. DMTTF shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-...

The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc. (OTCQB: BETRF)’s lead drug candidate LSD analog BETR-001 has shown positive results in a study assessing it as a potential treatment for mood disorders.  In preclinical and IND-enabling...

Psychedelics biotech company Cybin Inc. (NYSE: CYBN) shared progress updates for its two lead clinical development programs: proprietary deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD) and proprietary deuterated DMT compound CYB004 for the...

Delix Nabs 2 New Partners Neuroscience company Delix Therapeutics is partnering with Sweden-based Cellectricon and New York-based Expressive Neuroscience. The goal is to expedite Delix's drug development pipeline. Delix's compounds consist of small molecules capable of rapidly inducing...

Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO). The patents cover psychedelic-based...

Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy. Conducted at MAC Clinical Research in Manchester (UK), the randomized, blinded, placebo-controlled,...

Clinical-stage psychedelics biotech Reunion Neuroscience Inc. (NASDAQ: REUN) shared its unaudited financial results for the third quarter, as of Dec. 31, 2022. Cash and investments totaled $24.3 (CA$32.4) million by December 31, 2022. For the three and nine-month periods, R&D expenses were $2.6...

Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders Psychedelics firm Silo Pharma Inc. (NASDAQ: SILO) has received a US patent covering claims on the use of proprietary ketamine-based drug SPC-15 for the treatment of stress-induced...

(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains Next-Generation Psychedelics, MEAI - What And When Clearmind...